PROLIV: Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis

Sponsor
University Hospital, Montpellier (Other)
Overall Status
Unknown status
CT.gov ID
NCT03508388
Collaborator
University Hospital, Nīmes (Other), Narbonne Hospital (Other)
150
1
37.2
4

Study Details

Study Description

Brief Summary

Investigator seek to determine whether the volume of the liver can predict the survival after a decompensation of a patient suffering from chronic liver disease caused by excessive alcohol consumption (or alcoholic cirrhosis). Our hypothesis is that patients with a "small" liver have a lower survival compared to patients having a "normal" sized liver.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In this observational, prospective and multicentre clinical trial, investigator seek to determine the prognostic value of liver volume during an acute decompensation. Investigator plan to enroll admitted adult patients with acute decompensation of an alcoholic cirrhosis (abstinent or not), followed for one year or until death or liver transplantation. Liver volume will be evaluated using CT-scan or MRI reconstructions.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    150 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Prognostic Value of Liver Volume on Acute Decompensation of Alcoholic Cirrhosis, a Prospective Multicenter Observational Study
    Actual Study Start Date :
    Apr 25, 2018
    Anticipated Primary Completion Date :
    Dec 31, 2020
    Anticipated Study Completion Date :
    Jun 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. All cause mortality or liver transplantation [1 year]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Adult patients

    • Patient suffering from alcoholic cirrhosis (withdrawn or not)

    • Patient admitted in emergency for an alcoholic cirrhosis decompensation only

    • Prescription for a cutting imaging (CT scan or MRI) during hospitalisation

    • Alcohol consumption of more than 3 units per day for men and 2 units for women in average, over at least the last 5 years before the cirrhosis diagnosis

    • Patient suffering from decompensated cirrhosis defined by at least one of the following criteria : Model For End-Stage Liver Disease (MELD) score above or equal to 15, ascites needing iterative punctures, symptomatic bacterial ou fungal infections, acute digestive bleeding due to portal hypertension, hepatic encephalopathy defined by a West Haven score above or equal to 2

    Exclusion Criteria:
    • Nodule with typical criteria of hepatocellular carcinoma

    • B or C viral infections actives

    • Presence of transjugular intrahepatic portosystemic shunt (TIPS)

    • Presence of an occlusive thrombosis of the porta or one of the principal branches

    • Presence of a thrombosis of the sus-hepatic vein

    • Active extra-hepatic malignant tumor

    • Decompensated cardio-vascular disease

    • Patient unwilling to participate to the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Montpellier University Hospital Montpellier France 34295

    Sponsors and Collaborators

    • University Hospital, Montpellier
    • University Hospital, Nīmes
    • Narbonne Hospital

    Investigators

    • Principal Investigator: Jose URSIC BEDOYA, MD, UH Montpellier

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Montpellier
    ClinicalTrials.gov Identifier:
    NCT03508388
    Other Study ID Numbers:
    • RECHMPL18_0022
    First Posted:
    Apr 25, 2018
    Last Update Posted:
    Jan 7, 2020
    Last Verified:
    Jan 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Montpellier
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 7, 2020